Letromina Alpha Pharma

Letromina (Letrozole) is an oral, non-steroidal aromatase inhibitor. Unlike aminoglutethimide, letrozole does not inhibit the synthesis of adrenal steroids. Patients treated with letrozole, therefore, do not require glucocorticoid or mineralocorticoid replacement therapy. Letromina appears to be more effective and better tolerated than megestrol.

Mechanism of action

Letromina inhibits aromatase, an enzyme that catalyzes the last step in the synthesis of estrogens. Letromina  competitively binds to the haem of the cytochrome P450 subunit of aromatase without affecting the formation of adrenal corticosteroids, aldosterone, or thyroid hormones. Only serum estradiol concentrations are affected by Letromina. In postmenopausal women, the main source of circulating estrogens comes from the conversion of adrenal androgens and ovary (androstenedione and testosterone) to estrogens (estrone and estradiol) by aromatase in peripheral tissues. Inhibition of aromatase results in a more complete estrogen block than surgical ablation of the ovaries.

Please note that letrozole can also be used for post-cycle therapy for reloading. Letromina increases LH and FSH (hormones that activate their testes again to produce more testosterone). Letrozole is 2 to 5 times more potent than anastrozole and lasts longer in the body, but it takes a long time to begin. You should take Letromina  within 60 days, so that you can achieve a balance of blood plasma levels. Even more impressive, letrozole can reduce or eliminate the existing gyno! Thus, Letromina allows completely anti-estrogen, which protects during the restart after the cycle and eliminate the negative effects of steroids, which allows for an aesthetic advantage on the quality of the muscles.

Dosage

Take 1 or 2 mark 2.5 during or after the daily mg cycle.